Design of ruthenium-albumin hydrogel for cancer therapeutics and luminescent imaging

J Inorg Biochem. 2019 May:194:19-25. doi: 10.1016/j.jinorgbio.2019.02.002. Epub 2019 Feb 10.

Abstract

Improving cell uptake of metal compounds has became an important goal in the field of metal-based anticancer agents. This may combat platinum resistance and side effects seen commonly in current anticancer chemotherapy regimes. Here, we explore a novel degradable ruthenium-albumin hydrogel, which shows strong luminescence for cell imaging and high selectivity for cancer cells versus non-cancer cells. This is an early indication of the possibility of reducing unwanted side effects of metals by using bovine serum albumin hydrogel as a delivery strategy. This work provides a strong basis for development of a new class of metal-based cancer therapeutic agents.

Keywords: Albumin; Hydrogel; Imaging; Ruthenium; Therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Cattle
  • Cell Line, Tumor
  • Coordination Complexes / chemistry
  • Coordination Complexes / pharmacology*
  • Coordination Complexes / toxicity
  • Endopeptidase K / chemistry
  • Humans
  • Hydrogels / chemical synthesis
  • Hydrogels / chemistry*
  • Hydrogels / toxicity
  • Luminescent Agents / chemical synthesis
  • Luminescent Agents / chemistry*
  • Luminescent Agents / toxicity
  • Lysosomes / metabolism
  • Microscopy, Confocal
  • Mitochondria / metabolism
  • Proteolysis
  • Ruthenium / chemistry*
  • Serum Albumin, Bovine / chemistry*
  • Serum Albumin, Bovine / toxicity

Substances

  • Antineoplastic Agents
  • Coordination Complexes
  • Hydrogels
  • Luminescent Agents
  • Serum Albumin, Bovine
  • Ruthenium
  • Endopeptidase K